Podcasts

Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for CLL patients

Dr. Talha Munir, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

In this episode, Dr. Talha Munir (Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom) will discuss the first prospective data on minimal residual disease outcomes after fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of CLL in elderly or unfit patients enrolled in the Glow Study.

 

SUBSCRIBE TO BJH HEMATALKS SERIES